Charles Schwab Investment Management Inc. Grows Stake in AngioDynamics, Inc. (NASDAQ:ANGO)

Charles Schwab Investment Management Inc. increased its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 0.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 329,090 shares of the medical instruments supplier’s stock after acquiring an additional 2,270 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in AngioDynamics were worth $3,014,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in ANGO. FMR LLC increased its stake in AngioDynamics by 105.0% in the 3rd quarter. FMR LLC now owns 52,779 shares of the medical instruments supplier’s stock worth $411,000 after acquiring an additional 27,031 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of AngioDynamics by 110.4% in the third quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier’s stock worth $1,240,000 after purchasing an additional 83,622 shares during the last quarter. Walleye Capital LLC purchased a new stake in AngioDynamics in the third quarter valued at approximately $546,000. Quarry LP lifted its position in AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 2,471 shares during the last quarter. Finally, Systematic Financial Management LP grew its stake in AngioDynamics by 14.3% in the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock worth $18,752,000 after buying an additional 300,785 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright raised their price target on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Trading Down 0.6 %

Shares of ANGO opened at $9.83 on Friday. The firm has a market capitalization of $397.78 million, a price-to-earnings ratio of -1.75 and a beta of 0.56. The firm’s 50-day moving average price is $10.47 and its 200-day moving average price is $8.77. AngioDynamics, Inc. has a 1-year low of $5.47 and a 1-year high of $13.50.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. During the same period last year, the business earned ($0.05) EPS. AngioDynamics’s revenue was down .1% compared to the same quarter last year. On average, research analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. This trade represents a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.